Actively Recruiting

Phase 4
Age: 18Years +
All Genders
Healthy Volunteers
NCT05108818

Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults

Led by University of Pennsylvania · Updated on 2026-02-09

700

Participants Needed

1

Research Sites

338 weeks

Total Duration

On this page

Sponsors

U

University of Pennsylvania

Lead Sponsor

N

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Cellular and humoral immune responses before and after seasonal influenza vaccination will be assessed. Each year, up to 100 participants will be enrolled. To study age-specific differences in immune responses, participants with various years of birth will be enrolled. The investigators hypothesize that humans with different birth years will mount antibody and cellular responses of different specificities following seasonal influenza vaccination.

CONDITIONS

Official Title

Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults

Who Can Participate

Age: 18Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Provision of signed and dated informed consent form
  • Willingness to comply with all study procedures and attend all study visits
  • Aged 18 years and older
  • In good health based on self-reported medical conditions via an online survey
Not Eligible

You will not qualify if you...

  • Known allergic reactions to components of the study vaccine
  • Known latex allergy
  • History of severe reactions to previous influenza vaccines
  • History of Guillain-Barré syndrome within 6 weeks of a previous influenza vaccine
  • Immunosuppression due to illness or treatment, including anticancer therapy within past 36 months
  • Treatment with immunoglobulin or blood products within 3 months prior to enrollment
  • Active cancer (except stable non-melanoma skin or prostate cancer) or recent hematological malignancy treatment within 5 years
  • Long-term use of oral, parenteral, or high-dose inhaled steroids
  • Influenza vaccine received within 2 months prior to enrollment
  • Any acute or chronic medical condition that makes vaccination unsafe or interferes with study evaluation
  • Participation in another experimental agent study within 1 month before enrollment or planned during study
  • Intention to donate blood during the study
  • Any condition posing unacceptable risk or preventing protocol compliance
  • Pregnancy
  • Known infection with HIV, hepatitis B, or hepatitis C
  • Any condition that may interfere with successful study completion as judged by the principal investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

Loading map...

Research Team

S

Scott Hensley, PhD

CONTACT

E

Elizabeth Drapeau, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

BASIC_SCIENCE

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults | DecenTrialz